Sign up to save your podcasts
Or
Share FIGARO-DKD and FIDELITY Analysis: Key Takeaways
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
FIGARO-DKD and FIDELITY Analysis: Key Takeaways
CME credits: 0.25
Valid until: 31-08-2022
Claim your CME credit at https://reachmd.com/programs/cme/figaro-dkd-and-fidelity-analysis-key-takeaways/12827/
Two HOT LINE sessions presented at the ESC Congress 2021 may change the way you manage your patients with diabetes and CKD as you work to prevent their progression to ESRD and improve their cardiovascular outcomes. Drs. Rajiv Agarwal, George Bakris, and Bertram Pitt review data from the FIGARO-DKD trial and the FIDELITY Analysis to explore the evolving role of mineralocorticoid receptor antagonists (MRAs) as part of the overall treatment plan for patients with diabetes and CKD. Don’t miss this potentially practice-changing session!
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 31-08-2022
Claim your CME credit at https://reachmd.com/programs/cme/figaro-dkd-and-fidelity-analysis-key-takeaways/12827/
Two HOT LINE sessions presented at the ESC Congress 2021 may change the way you manage your patients with diabetes and CKD as you work to prevent their progression to ESRD and improve their cardiovascular outcomes. Drs. Rajiv Agarwal, George Bakris, and Bertram Pitt review data from the FIGARO-DKD trial and the FIDELITY Analysis to explore the evolving role of mineralocorticoid receptor antagonists (MRAs) as part of the overall treatment plan for patients with diabetes and CKD. Don’t miss this potentially practice-changing session!